2013 Emerging Science Series - June 19, 2013

Updated:Jan 2,2015


Cardiovascular Risk: From Epigenetics to Pharmacotherapy
Wednesday, June 19, 2013, Noon CDT


Robert O. Bonow, M.D., FAHA
Northwestern University Feinberg School of Medicine
Chicago, Ill.
Past AHA President and Chair of the Emerging Science Series Committee 

Christopher J. O'Donnell, M.D., MPH
National Heart, Lung and Blood Institute and NHLBI Framingham Heart Study
Framingham, MA

Neil J. Stone, M.D., FAHA, 
Feinberg School of Medicine, Northwestern University
Chicago, Ill.

Kiran Musunuru, M.D., Ph.D., M.P.H.,
Harvard University
Cambridge, Mass. 

Vasan Ramachandran M.D.,
Framingham Heart Study, Boston University
Boston, Mass.


CPT1A Methylation is a Novel Epigenetic Marker of Cardiovascular Risk 

Stella Aslibekyan, Ph.D., University of Alabama at Birmingham,  Birmingham, Ala.
Summary Slide | News Release | Abstract in Circulation | Review Article: Cardiovascular Epigenetics

The Incidence of Kidney Injury for Patients Treated with Intensive versus Less Potent Statin Therapy After an Acute Coronary Syndrome

Amy Sarma, M.D.,  Brigham and Women's Hospital, Boston, Mass.
Summary SlideNews Release | Abstract in Circulation


No CME/CE credit for this activity is provided.